Three of India's biggest CROs are joining forces to cash in on U.S. demand for outsourced drug services, launching a combined venture called Axcellerate Pharma.
Pharmacyclics and Johnson & Johnson are riding high on an accelerated approval for the blockbuster hopeful Imbruvica, and now they've tapped Catalent to aid in commercial manufacturing and ongoing clinical trials for the cancer drug.
Global CRO Covance has struck up a deal to expand its diagnostics capabilities in oncology trials, partnering with NeoGenomics to bolster its anatomic pathology and specialty lab testing.
Avalon Ventures is kick-starting the first biotech enterprise in its half-billion dollar portfolio deal with GlaxoSmithKline, launching a startup named Sitari Pharmaceuticals which will pursue research work out of Stanford University with an eye to developing a new drug for celiac disease.
The Vietnamese government is looking to boost its share of the world's clinical research market, signing a deal with CRO giant Quintiles to get the ball rolling.
Eli Lilly and the nonprofit Project A.L.S. are teaming up to boost the pipeline of potential drugs for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig' disease.
Combination cancer therapies are all the rage these days in the oncology field. Now two of the giant players in the cancer R&D arena have decided to match their top prospects to see if they can make a bigger impact on melanoma.
Unilife took another big step this week, signing a long-term contract agreement with generics maker Hikma Pharmaceuticals to use Unilife's injectable technology and netting up to $40 million in the process.
With the success of Erbitux and its patient-steering companion diagnostic fresh in mind, Qiagen and Eli Lilly have struck up their third partnership, reuniting to match genomic knowhow with drug development expertise.
Long-troubled biotech Cell Therapeutics has landed a big-name partner for its Phase III myelofibrosis drug, convincing Baxter to shell out $60 million upfront for a cut of pacritinib.